| Literature DB >> 26310908 |
Steven N Seyedin1, Jonathan E Schoenhals2, Dean A Lee3, Maria A Cortez2, Xiaohong Wang2, Sharareh Niknam2, Chad Tang1, David S Hong4, Aung Naing4, Padmanee Sharma5, James P Allison5, Joe Y Chang1, Daniel R Gomez1, John V Heymach6, Ritsuko U Komaki1, Laurence J Cooper7, James W Welsh1.
Abstract
Radiation therapy controls local disease but also prompts the release of tumor-associated antigens and stress-related danger signals that primes T cells to promote tumor regression at unirradiated sites known as the abscopal effect. This may be enhanced by blocking inhibitory immune signals that modulate immune activity through a variety of mechanisms. Indeed, abscopal responses have occurred in patients with lung cancer or melanoma when given anti-CTLA4 antibody and radiation. Other approaches involve expanding and reinfusing T or NK cells or engineered T cells to express receptors that target specific tumor peptides. These approaches may be useful for immunocompromised patients receiving radiation. Preclinical and clinical studies are testing both immune checkpoint-based strategies and adoptive immunotherapies with radiation.Entities:
Keywords: CAR T cells; OX40; abscopal effect; immune checkpoints; immunotherapy; ipilimumab; lung cancer; melanoma; nivolumab; radiation
Mesh:
Substances:
Year: 2015 PMID: 26310908 PMCID: PMC4825325 DOI: 10.2217/imt.15.65
Source DB: PubMed Journal: Immunotherapy ISSN: 1750-743X Impact factor: 4.196